MPWT
TRDA icon

MassMutual Private Wealth & Trust’s Entrada Therapeutics TRDA Stock Holding History

MassMutual Private Wealth & Trust’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.37K Hold
186
– – ﹤0.01% 2100
2026
Q1 		$2.35K Hold
186
– – ﹤0.01% 1934
2025
Q4 		$1.91K Buy
+186
New +$1.57K ﹤0.01% 2004

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

MassMutual Private Wealth & Trust's TRDA Position: Q2 2026 in Review

MassMutual Private Wealth & Trust held its Entrada Therapeutics (TRDA) position steady in Q2 2026 at 186 shares worth $1.37K. The position accounts for ﹤0.01% of the portfolio, ranked #2100.

MassMutual Private Wealth & Trust first reported a position in TRDA in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.35K in Q1 2026. 128 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • MassMutual Private Wealth & Trust held 186 shares of Entrada Therapeutics worth $1.37K as of Q2 2026.
  • MassMutual Private Wealth & Trust left its Entrada Therapeutics share count unchanged in Q2 2026.
  • Entrada Therapeutics made up ﹤0.01% of MassMutual Private Wealth & Trust's portfolio in Q2 2026, its #2100 holding.
  • MassMutual Private Wealth & Trust first reported a position in Entrada Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • MassMutual Private Wealth & Trust's Entrada Therapeutics position peaked at $2.35K in Q1 2026.
  • 128 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on MassMutual Private Wealth & Trust's 13F filing for Q2 2026, filed 2 Jul 2026.